This would result in RAC paying the treatment costs for the ~80% of patients that don't have EM AML. Would make the trial much more expensive.
The idea of Precision Oncology is that a biomarker (once developed) is used to screen patients for treatment. Before this biomarker is developed, PET scan is the primary screening method.
The premise of the two stratums is that it is for EM AML patients and there is an underlying hypothesis that their cancer over-expresses FTO.
This would result in RAC paying the treatment costs for the ~80%...
-
- There are more pages in this discussion • 90 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |